

# CE SARASOTA 2026



# TABLE OF CONTENTS

Table of Contents	2
Welcome	3
Industry Partners	4
Schedule	5
Course Notes	7
Speakers	9
Upcoming Conferences	12
Sponsor Information	14
Gold Industry Partners	17
Silver Industry Partners	21

# WELCOME



Dear Colleague,

Welcome to the **Optometric Education Consultants** (OEC) Live Conference Series! Whether you're joining us for the first time or returning, we appreciate your support.

Our **exhibitors play a key role** in making these meetings possible—helping to provide exceptional speakers, meals, and affordable registration. Please take a moment to visit them during breaks and join the **Industry Partner Game** for a chance to win a registration refund (100%, 50%, or 25%)! Three winners in total.

For Florida-licensed doctors, courses are Board-approved through CE Broker. For both **Florida (TQ) and Illinois (CEE)**, exams will be emailed 1–2 days after the conference (\$10 per course), with certificates issued immediately upon completion and CE Broker updated. Exams are only required if your state mandates them; otherwise, you may disregard the link. We also submit to CE Broker for **Michigan, South Carolina, and Texas**.

Our programs are designed with you in mind—balancing education, engagement, and relaxation. All **OEC conferences are COPE accredited** and those highlighted states-approved.

Looking for additional hours? If your state allows, explore our COPE-approved Webinar Series or Enduring Courses, available at your convenience.

For more information on OEC [Webinars](#) [Asynchronous](#) [Live Conferences](#)

## 2026 - 2027

Rosenberg & OEC Abroad, May 20 - 22 - Amsterdam, Netherlands

Sunshine State Summer Conference, June 26 - 28 - Orlando, FL

OEC Northern Escape, August 21 - 23 - Quebec City, QC

Music City Fall Classic, October 23 - 25 - Nashville, TN

Detroit Power Hours, November 7 - 8 - Detroit/Dearborn, MI

Again thank-you for trusting OEC with your education needs!

Greg & Joe

Jenna, Maureen, Vanessa & Helen

# INDUSTRY PARTNERS

## Diamond Partners

Apellis

BAUSCH + LOMB

## Gold Industry Partners

Alcon

 Dompé

## Silver Industry Partners

  
CooperVision®

DAVID KEITH  
OPHTHALMIC

EssilorLuxottica | Eye Care

icare

INNOVA  
SYSTEMS

LENZ  
THERAPEUTICS

MedTech  
International group

ORASIS  
PHARMACEUTICALS™

PHARMANEX®

SCIENCEBASED  
HEALTH.

SUN  
OPHTHALMICS

tenpoint  
THERAPEUTICS

Théa  
let's open our eyes

ULTRA  
MEDICAL  
FORMERLY THE DRY EYE DOCTOR

US EYE  
BETTER TOGETHER

VIRTUALVISION

VISION  
ELEMENTS™

VISIONIX

This activity is supported with an unrestricted educational grants from Lenz Therapeutics & Sun Pharma

# SCHEDULE



Optometric Education Consultants  
 CE Sarasota, Sarasota Westin  
 April 11-12, 2026

Saturday April 11, 2026		
7:00 am – 8:00 am	Registration & Breakfast with Exhibitors	Hours
8:00 am – 8:30 am	Breakfast Symposium with Alcon <b>TRYPTYR: A First-In-Class Neuromodulator Eye Drop</b> <i>Cecelia Koetting, OD, FAAO</i>	No CE credit
8:30 am – 10:10 am	<b>Two Voices, One Mission: New Approaches for OSD</b> <i>Cecelia Koetting, OD and Greg Caldwell, OD</i>	2 hours CEE/TQ
10:10 am – 10:40 am	Break with Exhibitors	
10:40 am – 12:20 pm	<b>Will the Real Glaucoma, Please Stand Up</b> <i>Cecelia Koetting, OD</i>	2 hours CEE/TQ
12:20 pm – 1:35 pm	Lunch Symposium with Bausch & Lomb <b>Fast Tracking Dry Eye Management- Integrating Science and Practice</b> <i>Scott Han, OD, FAAO</i> <b>A Branded First- Line Treatment, From the Start</b> <i>Scott Han, OD, FAAO</i>	
1:35 pm – 3:15 pm	<b>OCT and Visual Field Pearls Through Glaucoma Case Discussion</b> <i>Joseph Sowka, OD and Greg Caldwell, OD</i>	2 hours CEE/TQ
3:15 pm - 3:45 pm	Break with Exhibitors	
3:45 pm – 5:25 pm	<b>Eye on Neuro-Op Disease</b> <i>Joseph Sowka, OD, Jody Abrams, MD, Usma Chatha, DO</i>	2 hours CEE/TQ
5:30 pm – 6:30 pm	<b>Reception at EVOQ Terrace</b>	

# SCHEDULE



Optometric Education Consultants  
 CE Sarasota, Sarasota Westin  
 April 11-12, 2026

Sunday April 12, 2026		
7:00 am – 8:00 am	Registration & Breakfast with Exhibitors	
8:00 am – 8:30 am	Breakfast Symposium with Dompe'  <b>Identification and Treatment of Neurotrophic Keratitis</b> <i>Mark Eves, OD</i>	
8:30 am – 10:10 am	<b>Latest Advances in Eye Care Technology</b> <b>Innovations in Early Detection and Management</b> Greg Caldwell, OD	2 hours CEE/ TQ
10:10 am – 10:40 am	Break with Exhibitors	
10:40 am – 12:20 pm	<b>Perils of the Pathway</b> <i>Drew Rixon, OD</i>	2 hours CEE/TQ
12:20 pm – 1:35 pm	Lunch Symposium with Apellis  <b>Optometrists' Guide to GA: Best Practices for Early Detection</b> <i>Jaclyn Kovach, MD &amp; Greg Caldwell, OD</i>	
1:35 pm – 3:15 pm (Concurrent)	<b>Prevention of Medical Errors for Optometrists</b> <i>Joseph Sowka, OD &amp; Barry Frauens, OD</i>	2 hours
1:35 pm – 3:15 pm (Concurrent)	<b>Developing a Flare for Uveitis</b> <i>Drew Rixon, OD</i>	2 hours CEE/TQ
3:15 pm – 3:25 pm	Break	2 hours
3:25 pm 5:05 pm (Concurrent)	<b>Florida Jurisprudence</b> <i>Joseph Sowka, OD / Barry Frauens, OD</i>	2 hours
3:25 pm 5:05 pm (Concurrent)	<b>Pharmaceutical Complications Every Optometrist Should Know</b> <b>When Good Drugs Go Bad</b> <i>Greg Caldwell, OD</i>	2 hours CEE/TQ

# COURSE NOTES



# COURSE NOTES

**DOWNLOAD**

**Two Voices, One Mission: New Approaches for OSD**

Cecelia Koetting, OD & Greg Caldwell, OD

**DOWNLOAD**

**Will the Real Glaucoma Please Stand Up**

Cecellia Koetting, OD

**DOWNLOAD**

**OCT and Visual Field Pearls Through Glaucoma Case Discussion**

Joseph Sowka, OD & Greg Caldwell, OD

**DOWNLOAD**

**Eye on Neuro-Op Disease**

Joseph Sowka, OD; Jody Abrams, MD; Usma Catha, OD

**DOWNLOAD**

**Latest Advances in Eye Care Technology - Innovations in Early Detection and Management**

Greg Caldwell, OD

**DOWNLOAD**

**Perils of the Pathway**

Drew Rixon, OD

**DOWNLOAD**

**Prevention of Medical Errors**

Joseph Sowka, OD & Barry Frauens, OD

**DOWNLOAD**

**Developing a Flair for Uveitis**

Greg Caldwell, OD

**DOWNLOAD**

**Florida Jurisprudence**

Joseph Sowka, OD & Barry Frauens, OD

**DOWNLOAD**

**Pharmaceutical Complications Every Optometrist Should Know - When Good Drugs Go Bad**

Greg Caldwell, OD

# SPEAKERS



## **Jody Abrams, MD**

Dr. Abrams was born and raised in Covington, Louisiana where he attended the local public schools. Dr. Abrams was accepted to the Louisiana State University system pre-matriculation program for college and medical school which meant that before graduating high school he was accepted to both college, LSU-Shreveport, and medical school at LSU Health Science Center in Shreveport. While in both high school and college he was a student athletic trainer helping in football, baseball and basketball. He obtained a BS in Biology in 1998 from LSU-S and then his MD from LSUHSC-S in 2002. During medical school he was elected to the junior Alpha Omega Alpha (AOA) honor society which is given to the top 5% of the nation's medical school classes.

Having done a lot of previous work with orthopedic doctors in the athletic world, he considered a career in this field; but while on the ophthalmology rotation in medical school he fell in love with this specialty. After completing an internship in Internal Medicine at LSUHSC-S, he went on to complete a residency in Ophthalmology at LSUHSC-S, including serving as chief resident during his last year. Dr. Abrams then traveled to what is considered the "frozen north" Detroit, Michigan to spend a year doing an Oculoplastic/Neuro-Ophthalmology fellowship under the supervision of Dr. Thomas Spoor, a well-respected pioneer in both fields. He became board certified in Ophthalmology in 2008. After completing all of his training, he practiced in Chattanooga, Tennessee in a private practice for 3 years. However, due to his love of the water and sailing, he joined the Sarasota Retina Institute in the summer of 2011.



## **Greg Caldwell, OD, FAAO**

Greg Caldwell, OD, is a 1995 graduate of the Pennsylvania College of Optometry. He completed a one-year residency in primary care and ocular disease at The Eye Institute in Philadelphia Pennsylvania. He is a fellow of the American Academy of Optometry (AAO) and a Diplomate of the American Board of Optometry (ABO).

He currently works in Duncansville and Johnstown, Pennsylvania as an ocular disease consultant. Dr. Caldwell's primary focus is the diagnosis and management of anterior and posterior segment ocular disease and he has been a participant in multiple FDA investigations. Dr. Caldwell has lectured extensively throughout the county and over twelve countries internationally. In 2010 he served as President of the Pennsylvania Optometric Association (POA) and served on the AOA Board of Trustees 2013-2016. He is President of the Blair/Clearfield Association for the Blind.

# SPEAKERS



## **Usma Chatha, DO**

Dr. Usma Chatha relocated from Pakistan to Pittsburgh, Pennsylvania at age 9. She went to local public schools within the Pittsburgh area. Throughout her primary education Dr. Chatha was an active volunteer at Family House and the local hospitals which fueled her passion for medicine. She stayed in Pittsburgh to attend the University of Pittsburgh for her undergraduate studies. Throughout her college years Dr. Chatha worked at the University of Pittsburgh Medical Center as a nurse's aide. She graduated with magna cum laude with a BS in Neuroscience and minored in chemistry and religious studies. Dr. Chatha then went on to obtain her medical degree at the Philadelphia College of Osteopathic Medicine (PCOM). Her love for neuroscience and visual processing led her to begin volunteering at Wills Eye Hospital and ultimately led her to pursue Ophthalmology residency at PCOM. Upon completion of her residency, she was accepted as the first class of a 2 year fellowship in Neuro-Ophthalmology and Oculoplastics at Wills Eye Hospital. Dr. Chatha decided to relocate to Sarasota, Florida to be closer to family and the year round beautiful weather. She is very excited to join Sarasota Retina Institute and be able to offer subspecialty services in both Neuro-Ophthalmology and Oculoplastic Surgery. Dr. Chatha is very passionate about her work and will go to great lengths to make sure her patients receive the care they need and deserve. Outside of the office Dr. Chatha enjoys spending time with her husband who is an interventional pulmonologist at the Lung Associates of Sarasota, experimenting with new cooking recipes, trail walking/biking, and exploring Sarasota and the surrounding areas.



## **Cecelia Koetting, OD**

Dr. Koetting is an Assistant Professor at the University of Colorado School of Medicine in the Department of Ophthalmology in Denver, CO. Her primary focus is in anterior segment and ocular surface disease, neuro-optometry, and peri-operative care. She partakes in clinical research and has served Externship Director and adjunct faculty for several schools and colleges of optometry.

Dr. Koetting is a member of Intrepid, a fellow in the American Academy of Optometry, a diplomate of the American Board of Optometry, an active member of AOA and has served as both local and state officers within AOA. She was named young Optometrist of the year by the state of Virginia. Dr. Koetting lectures locally, nationally and internationally at conferences, continually contributes articles to and serves on editorial board for multiple publications.

# SPEAKERS



## **Barry Frauens, OD, FAAO**

Dr. Barry J. Frauens graduated with honors from Nova Southeastern University College of Optometry in 1996 and thereafter completed a one-year residency program in Primary Care optometry at the Pennsylvania College of Optometry.

Dr. Frauens is a full-time faculty member at Nova Southeastern University College of Optometry where he holds the rank of Associate Professor and serves as the Chief of the Primary Care Service at the N. Miami Beach Clinic. Dr. Frauens served as Chair of the Department of Clinics as well for nearly a decade.

Dr. Frauens is a past President of the Florida Optometric Association and the Broward County Optometric Association. He is the 2002 recipient of the BCOA 'Optometrist of the Year' award, the 2003 'NSU Distinguished Alumni Achievement' award, the 2006 FOA 'Optometrist of the Year' award and the 2017 FOA Edward K. Walker 'Optometrist of the Decade' award.

Dr. Frauens has published numerous journal articles in the refereed literature. He is a fellow of the American Academy of Optometry, a fellow of the Optometric Glaucoma Society, a Fellow of the Optometric Retina Society and is one of the first Optometrists in the profession to become Board Certified by the American Board of Optometry. Dr. Frauens has lectured locally, regionally, nationally and internationally covering numerous subjects in anterior and posterior segment ocular disease management as well as prevention of medical errors. His current research interests include glaucoma.



## **Joseph Sowka, OD, FAAO, Diplomate**

Dr. Joseph Sowka is an attending optometric physician at Center for Sight in Sarasota, Florida, a large medical-surgical practice where he focuses on glaucoma management and neuro-ophthalmic disease. He was formerly Professor of Optometry at Nova Southeastern University College of Optometry for 28 years where he served as Chief of The Advanced Care Service and Director of the Glaucoma Service at the College's Eye Institute. He was the Program Coordinator and Supervisor for the Ocular Disease Residency. Dr. Sowka is a founding member of both the Optometric Glaucoma Society and Optometric Retina Society. He is also the Founder and Chair of the Neuro-Ophthalmic Disorders in Optometry Special Interest Group for the American Academy of Optometry. Dr. Sowka is a Glaucoma Diplomate of the American Academy of Optometry. He is a partner and co-owner of Optometric Education Consultants.

# UPCOMING CONFERENCES



REGISTER  
NOW

## OEC & RSO Abroad in Amsterdam, Netherlands May 20-22, 2026

Van der Valk Hotel  
Amsterdam Amstel  
Joan Muyskenweg 20  
Amsterdam, 1096 CJ  
Netherlands



REGISTER  
NOW

## Sunshine State Summer Conference June 6-8, 2025

Disney's Contemporary Resort  
4600 World Dr,  
Lake Buena Vista, FL 32830

© Disney



REGISTER  
NOW

## OEC Northern Escape August 21-23, 2026

Hilton Quebec  
1100, boul. René-Lévesque Est.,  
Quebec, QC G1R 4P3, CA

# UPCOMING CONFERENCES

SAVE  
THE  
DATE



## Music City Fall Classic October 23-25, 2026

Hilton Doubletree  
315 4th Avenue North  
Nashville, TN 37219

REGISTER  
NOW



## Detroit Power Hours November 7-8, 2026

DoubleTree by Hilton Detroit  
5801 Southfield Freeway,  
Detroit, MI 48228

SAVE  
THE  
DATE



## Pittsburgh Primary Eyecare Conference February 20-21, 2027

Doubletree by Hilton  
Pittsburgh Green Tree  
500 Mansfield Avenue  
Pittsburgh, PA

# SPONSOR INFORMATION





# SYFOVRE<sup>®</sup>

(pegcetacoplan injection)

Visit us at the SYFOVRE exhibit



Learn more at  
[SyfovreECP.com](https://www.syfovreecp.com)

Apellis

APELLIS<sup>®</sup>, SYFOVRE<sup>®</sup> and their respective logos  
are registered trademarks of Apellis Pharmaceuticals, Inc.  
©2024 Apellis Pharmaceuticals, Inc. 5/24 US-PEGGA-2300183 v2.0



**Miebo®**  
(perfluorohexyloctane  
ophthalmic solution)

**Learn more at [MIEBO-ECP.com](https://MIEBO-ECP.com)**

**BAUSCH + LOMB**

©2024 Bausch + Lomb

MBO.0595.USA.24



**GOLD  
INDUSTRY  
PARTNERS**



**Alcon**

OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) is indicated for the treatment of neurotrophic keratitis.



See more clinical data  
OXERVATE.com/hcp



## THE FIRST AND ONLY FDA-APPROVED TREATMENT OPTION FOR PATIENTS WITH NEUROTROPHIC KERATITIS<sup>1,2</sup>

The efficacy and safety of OXERVATE® were established in the largest combined clinical trial program conducted in patients with neurotrophic keratitis.<sup>3,4</sup>

### Important Safety Information

#### WARNINGS AND PRECAUTIONS

##### Use with Contact Lenses

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

##### Eye Discomfort

OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.

#### ADVERSE REACTIONS

In clinical trials, the most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Eye pain may arise as corneal healing occurs. Other adverse reactions occurring in 1% to 10% of OXERVATE patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

#### USE IN SPECIFIC POPULATIONS

##### Pregnancy

There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks.

##### Lactation

The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE.

##### Pediatric Use

The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in pediatric patients 2 years of age and older is supported by evidence from adequate and well-controlled trials of OXERVATE in adults with additional safety data in children.

#### INDICATION

OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) is indicated for the treatment of neurotrophic keratitis.

**DOSAGE AND ADMINISTRATION** **SEE YOUR LOCAL ALCON SALES REPRESENTATIVE FOR MORE INFORMATION.**  
Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

To report ADVERSE REACTIONS, contact Dompé U.S. Inc. at 1-833-366-7387 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see the Brief Summary of full Prescribing Information for OXERVATE on the following page.

**References:** 1. OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) [US package insert]. San Mateo, CA: Dompé U.S. Inc.; 2024. 2. FDA approves first drug for neurotrophic keratitis, a rare eye disease. U.S. Food and Drug Administration; August 22, 2018. Accessed December 3, 2024. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-neurotrophic-keratitis-rare-eye-disease> 3. Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. *Ophthalmology*. 2018;125:1332-1343. 4. Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multi-center randomized vehicle-controlled pivotal trial. *Ophthalmology*. 2020;127:14-26.



© 2025 Dompé U.S. Inc. All rights reserved.  
US-OXE-2200017.2 3.2 06/25

oxervate®   
(cenegermin-bkbj ophthalmic  
solution) 0.002% (20 mcg/mL)

## Brief Summary of full Prescribing Information

Consult the full Prescribing Information for complete product information, available at [www.oxervate.com/prescribing-information](http://www.oxervate.com/prescribing-information).

### INDICATIONS AND USAGE

OXERVATE® (cenegermin-bkjb) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.

### DOSAGE AND ADMINISTRATION

#### General Dosing Information

Contact lenses should be removed before applying OXERVATE and may be reinserted 15 minutes after administration.

If a dose is missed, treatment should be continued as normal, at the next scheduled administration.

If more than one topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel or other viscous eye drops.

#### Recommended Dosage and Dose Administration

Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

### WARNINGS AND PRECAUTIONS

#### Use with Contact Lens

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkjb onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

#### Eye Discomfort

OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.

### ADVERSE REACTIONS

#### Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

In two clinical trials of patients with neurotrophic keratitis, a total of 101 patients received cenegermin-bkjb eye drops at 20 mcg/mL at a frequency of 6 times daily in the affected eye(s) for a duration of 8 weeks. The mean age of the population was 61 to 65 years of age (18 to 95). The majority of the treated patients were female (61%). The most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Eye pain may arise as corneal healing occurs.

Other adverse reactions occurring in 1% to 10% of OXERVATE patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

### Postmarketing Experience

The following adverse reactions have been identified during postapproval use of OXERVATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Eye disorders:* eye irritation, blepharitis (including eyelid margin crusting and eyelid edema) and corneal neovascularization.

### USE IN SPECIFIC POPULATIONS

#### Pregnancy

##### Risk Summary

There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks.

Administration of cenegermin-bkjb to pregnant rats or rabbits during the period of organogenesis did not produce adverse fetal effects at clinically relevant doses. In a pre- and postnatal development study, administration of cenegermin-bkjb to pregnant rats throughout gestation and lactation did not produce adverse effects in offspring at clinically relevant doses.

#### Lactation

##### Risk Summary

There are no data on the presence of OXERVATE in human milk, the effects on breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE.

#### Pediatric Use

The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in this population is supported by evidence from adequate and well-controlled trials of OXERVATE in adults with additional safety data in pediatric patients from 2 years of age and older.

#### Geriatric Use

Of the total number of subjects in clinical studies of OXERVATE, 43.5% were 65 years old and over. No overall differences in safety or effectiveness were observed between elderly and younger adult patients.

### NONCLINICAL TOXICOLOGY

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

##### Carcinogenesis and Mutagenesis

Animal studies have not been conducted to determine the carcinogenic and mutagenic potential of cenegermin-bkjb.

##### Impairment of fertility

Daily subcutaneous administration of cenegermin-bkjb to male and female rats for at least 14 days prior mating, and at least 18 days post-coitum had no effect on fertility parameters in male or female rats at doses up to 267 mcg/kg/day (1709 times the MRHOD).

In general toxicology studies, subcutaneous and ocular administration of cenegermin-bkjb in females was associated with ovarian findings including persistent estrus, ovarian follicular cysts, atrophy/reduction of corpora lutea, and changes in ovarian weight at doses greater than or equal to 19 mcg/kg/day (119 times the MRHOD).





**SILVER  
INDUSTRY  
PARTNERS**



Ivan, age 9

Left eye: -4.75 D Right eye: -4.25 D

Ivan, age 13

Left eye: -5.00 D Right eye: -5.50 D

# TODAY IS THE DAY.

Prescribe the only contact lens treatment to help protect a child's blurry vision from getting worse.\*†‡1,2

## Meet Ivan, a real-life MiSight® 1 day\* patient.

After years of changing prescriptions, Ivan started MiSight® 1 day contact lenses at age 9.

4 years later, his myopia progression has slowed drastically, tracking similarly to the average results found in the MiSight® 1 day 6-year study!§1



Join the thousands of doctors wvcating parents about correcting vision AND treating myopia with MiSight® 1 day.\*†‡1,2 Choose the only FDA-approved\* contact lens for myopia control in age-appropriate children.

**MISIGHT® TODAY. ANYTHING TOMORROW.**

**GET STARTED TODAY WITH QUICKSTART™ TOOLS AND RESOURCES.**



\*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†MiSight® 1 day, designed for myopia control, shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6 years. n=40

‡Compared to a single-vision 1-day lens.

§Results may vary. Over a 3-year period, MiSight® 1 day reduced myopia progression on average by 59% compared to a single-vision contact lens.

◇ActivControl® technology in MiSight® 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.

1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.

2. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.

CooperVision®



IPL with RF!

# DAVID KEITH

---



---

# OPHTHALMIC


[www.davidkeith.com](http://www.davidkeith.com)



**icare**  
tonometer



**SURSIGHT**<sup>®</sup>  
Ocular Membrane Allograft  
Manufactured by SURGENIX



# EssilorLuxottica | Eye Care

LENSCRAFTERS®

For Eyes 

OPTICAL®

PEARLEVISION®



**Follow your vision.** With over 2,000 EssilorLuxottica affiliated locations across four leading brands, including LensCrafters, For Eyes, Target Optical, and Pearle Vision, you have a variety of employment and ownership options to choose from, such as independent practice, franchise, and full- or part-time employment.


We are committed to ensuring success for you and your career. You'll take pride in providing patients with the highest-quality vision care.

**Join us, and let's see your vision through.**

## Want to learn more?

Connect with an EssilorLuxottica Eye Care team member today.





## iCare EIDON® Family

# Excellent Ultra-Widefield image quality covering up to 200°



Using white LED light provides TrueColor detail-rich retinal images from the macula to the periphery



Confocal Technology allows scanning through media opacities and pupils as small as 2.5 mm resulting in high-resolution images



Fully automated easy-to-use family of products with advanced features and multiple imaging modalities



Learn more  
[icare-world.com](https://icare-world.com)



iCare is a trademark of Icare Finland Oy, Icare Finland Oy, Icare USA, Inc., iCare World Australia Pty Ltd, China iCare Medical Technology Co. Ltd, Thirona Retina B.V. and CENTERVUE S.P.A., are parts of Revenio Group and represent the brand iCare. iCare EIDON is a trademark or a registered trademark of Icare Finland Oy in the EU and the USA and/or other countries. CENTERVUE S.P.A. is the legal manufacturer of EIDON. Not all products, accessories, services or offers are approved in every market. Approved labeling and instructions may vary from one country to another. This material is intended for healthcare professionals only. ©2025 Icare Finland Oy. All rights reserved. ICARE-EIDON-FAMILY-UWFL-TRADE-ADS-017-REV02-EN-2025-02-US

CE 0123

INNOVA  
SYSTEMS



**L E N Z**

T H E R A P E U T I C S



**MediTech**  
International group

**Qlosi**<sup>™</sup> (pilocarpine HCl  
ophthalmic solution) 0.4%

THE PRESBYOPIA DROP

# Single digits. Double take.

- **All** adverse events in single digit percentages
- **0%** double-digit side effects
- **~8 of 10** patients achieved 20/40 near (7-point - driver's license font)

**Choose the drop that  
puts patient comfort first**

#### Indication and Usage

Qlosi<sup>™</sup> is indicated for the treatment of presbyopia in adults.

#### Important Safety Information

##### CONTRAINDICATIONS

Hypersensitivity

##### WARNINGS AND PRECAUTIONS

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

Qlosi is not recommended to be used when iritis is present.

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

##### ADVERSE REACTIONS

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Please see full Prescribing Information here:  
<https://www.qlosi.com/prescribing-information>

©2025 Orasis Pharmaceuticals, Inc. All Rights Reserved.

Qlosi, Orasis Pharmaceuticals, the Orasis Pharmaceuticals logo, and certain other trademarks herein are trademarks of Orasis Pharmaceuticals, Inc. QLO.00384 10/2025



**BLINKR<sub>x</sub>**



# Introducing Prysm iO

The next Generation of Antioxidant Scanning Has Arrive for \$299!

Meet Prysm iO — the world's most advanced non-invasive antioxidant scanner, providing real-time insights into antioxidant status, cellular health, and nutrition deficiencies. Built on the trusted Raman database and enhanced by machine learning, Prysm iO delivers science-backed accuracy and measurable results you can trust.

Starting January 2026, you can own your Prysm iO device for just \$299 — no leases, no contracts, and no recurring fees.

With its new AI-powered recommendation system, Prysm iO not only measures internal nutrition — it helps guide you and your patients to better personalized outcomes.

You can't optimize what you don't measure. Prysm IO makes measuring, tracking, and improving internal wellness easier, smarter, and more rewarding than ever.



GET SCANNED  
TO FIND OUT YOUR  
ANTIOXIDANT LEVEL





SCIENCEBASED  
HEALTH®



# CEQUA<sup>®</sup> COULD BE THE CHANGE YOUR PATIENTS ARE KING FOR



**Start your patients on CEQUA**

# SAY HELLO TO



# YUVEZZI™

(carbachol and brimonidine tartrate  
ophthalmic solution) 2.75%/0.1%

**NOW AVAILABLE**

Sign up for product updates at [YUVEZZIecp.com](https://www.YUVEZZIecp.com)

**tenpoint**  
THERAPEUTICS

© 2026 Tenpoint Therapeutics, Ltd. ALL RIGHTS RESERVED  
YUVEZZI is a trademark of Visus Therapeutics, Inc.  
TENPOINT is a trademark of Tenpoint Therapeutics Holding Limited.  
Visus Therapeutics, Inc., an affiliate of Tenpoint Therapeutics, Ltd., Seattle, Washington, 98109, USA.  
MAT-US-YZ-0214 03/26




# Professional Dry Eye Treatment

## SOOTHE - RESTORE - REFRESH

### ULTRA PRO COMPRESS™

Advanced Anti-Microbial Dry Eye Treatment Pack



#Pro100 Includes: A Professional Ophthalmic Compress, ULTRA Eyelid Wipes, and Storage/Travel Box



Ultra Lid Wipes™ #6004



Ultra Tea Tree Wipes™ #6008

## Soothing Therapy for Dry Eye Relief

Experience natural, effective relief for Dry Eye Disease (DED), Blepharitis, Meibomian Gland Dysfunction (MGD), Chalazion, Gritty Eyes, Sore Eyes, Tired Eyes, Migraines, and more.

Filled with self-hydrating ULTRA Beads™, this innovative compress delivers consistent, soothing, moist heat therapy to help ease symptoms like grittiness, irritation, and sore eyes.

- **ULTRA Effective** - constant 8 to 10 minutes of moist heat
- **ULTRA Easy** - just 20 to 30 seconds in the microwave
- **ULTRA Versatile** - can be heated in a microwave/oven, plus used for cold therapy
- **ULTRA Hygienic** - material and Ultra Beads™ are both anti-microbial
- **ULTRA Clean** - removable machine wash cover
- **ULTRA Comfortable** - adjustable head strap for secure fit

For more information, please call: 470-374-5305 or Toll Free: 833-4DRYEYE  
email: [info@thedryeyedoctor.net](mailto:info@thedryeyedoctor.net) | [www.thedryeyedoctor.net](http://www.thedryeyedoctor.net)



# THE FUTURE IS IN YOUR HANDS

# iyuzeh™

(latanoprost ophthalmic solution) 0.005%



Visit [iyuzeh.com](https://iyuzeh.com) to learn more.



US EYE

---

BETTER TOGETHER

Untethered, Fast, and Accurate




# Level up your Practice with a VR Visual Field!



## THE VIRTUAL EYE EXPERIENCE

Revolutionize the way you deliver care, meeting patients where they are.

- 📄 Gold-standard tests and reports—but smarter form factor
- 😊 Comfortably assess patients of all ages, and reduce testing fatigue and chair time
- ⚙️ Untethered design eliminates the need for a dedicated dark room
- 🎧 VR assistant instructs and coaches patients in 40+ languages, freeing up staff to perform other tasks



## Recognizable Reporting

Examination records can be printed or downloaded and saved to your EMR system.

Schedule a virtual demo

## VR VISUAL FIELD MUST-HAVES


	The Virtual Eye Advantage	Why It Matters
<b>Clinical confidence</b>	Built on trusted perimetry protocols	If you can't trust the data, nothing else matters.
<b>Workflow efficiency</b>	Fast setup, minimal supervision	Efficiency isn't a bonus — it's the business case.
<b>Patient experience</b>	Comfortable, accessible testing	Better comfort = better data = better long-term outcomes.
<b>Integration</b>	EHR / DICOM compatible	If it slows documentation, it slows adoption.
<b>Cost and ROI</b>	Lower cost, scalable, no heavy maintenance	You can maximize ROI without the overhead and expensive upkeep.

VISION  N  
ELEMENTS™

**INTEGRATED TECHNOLOGY TO OPTIMIZE YOUR PRACTICE**



**WORKFLOW FLEXIBILITY**



**THE COMPREHENSIVE RANGE OF OPHTHALMIC SOLUTIONS**

**Consistent & accurate refraction with Eye Refract**

- Open-field & binocular
- See more patients due to increased efficiency
- Complete refraction in around 4 minutes

**Tele-optometry & ocular telehealth services powered by 20/20NOW**

- Integrate our devices with 20/20NOW's platform & team of remote optometrists

**One-touch diagnostic anterior & posterior segment screening with VX 100 series or VX 650**

- Autorefractometry/Keratometry, topography, retroillumination & wavefront aberrometry
- Automated tracking, measurement, & focusing
- Optional anterior chamber analysis, pachymetry, Scheimpflug imaging, non-contact tonometry, anterior/posterior tomography, & dry eye analysis

**SEE BOOTH FOR OEC CONGRESS SPECIALS!**

**Revolutionary multimodality imaging with Optovue Solix**

- NEW optional Topography Module available!
- The **ONLY** OCT with FDA-cleared OCT-A metrics
- FullRange® Retinal 16x6.25mm scan
- FullRange® Anterior Chamber 18x6.25mm scan
- Ultra fast 120kHz scan speed
- Higher scan density & precision vs. other OCTs/OCT-As
- Integrated fundus camera + external color & IR imaging
- And much more, ask us for details at booth!



**Experience perfection with Briot Couture**

- Integrated wavefront lens analysis
- Torque Management System (TMS) software
- User friendly
- Reduced remakes
- Increase efficiency & output for maximized ROI

